HPV Viral Load in Predicting the Prognosis of LSIL

Launched by FUJIAN MATERNITY AND CHILD HEALTH HOSPITAL · Sep 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the amount of human papillomavirus (HPV) in the body can help predict the outcomes for women with low-grade squamous intraepithelial lesions (LSIL), which are early changes in cervical cells that may lead to cancer. Researchers want to understand if higher levels of HPV, especially certain types, could indicate a greater risk of developing more serious cervical problems in the future. This information could improve how doctors screen for cervical cancer and manage patients with HPV infections.

To participate in this study, women aged 20 and older who have been diagnosed with LSIL in the last three months may be eligible. However, some women, such as those recently pregnant, those with a history of certain surgeries or treatments, or those who have recently used specific medications, will not be able to take part. Participants can expect to provide samples for testing and help contribute to important research that may ultimately improve health outcomes for women dealing with HPV and related conditions.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged 20 and over.
• • The result of cervical histopathology in the last 3 months was low-grade squamous intraepithelial lesion (LSIL).
• • Non pregnant people with sexual history.
• • Asexual life, no vaginal medication or flushing before 72 hours of sampling.
• Exclusion Criteria:
• • Within 8 weeks after pregnancy or postpartum.
• • Patients with history of genital tract tumor.
• • History of HPV vaccination.
• • Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
• • In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
• • Use antibiotics or vaginal microecological improvement products in recent 1 month.